

Link: <https://bwhealthcareworld.businessworld.in/article/Pharma-Body-OPPI-Appoints-Anil-Matai-As-Director-General/17-10-2023-495261/>

Magazine Issue



Registrar Corp
U.S. Food Label Services

HOME

HEALTHCARE PROVIDERS

TECHNOLOGY

INSURANCE

FINANCE

REGULATORY

PEO

SUBSCRIBE TO PRINT

Pharma Body OPPI Appoints Anil Matai As Director-General

Follow

Anil Matai, a seasoned general management professional, has extensive experience in the Life Sciences space having worked across MNCs including spearheading operations across Novartis India, GSK India, and Global Pharma, Dubai



The Organisation of Pharmaceutical Producers of India (OPPI), which represents global research-based pharmaceutical companies, has appointed Anil Matai as its Director General, the organisation said in a statement on Monday.

Anil Matai, a seasoned general management professional, has extensive experience in the Life Sciences space having worked across MNCs including spearheading operations across Novartis India, GSK India, and Global Pharma, Dubai.

After superannuating as Managing Director of Zydus Healthcare, Anil was engaged as Senior Advisor - Life Sciences at IQVIA Consulting and Information Services India, and most recently as Operating Partner at Jashvik Capital - a mid-market Private Equity Fund focused on Healthcare and Consumer sector. Anil has functioned on the boards of Zydus Healthcare, Bayer Zydus Pharma, Novartis Healthcare and Biochem Pharmaceutical Industries.

As an influential leader, his proven skillsets in operations leadership, collaborative working, stakeholder management, have contributed towards market-leading results. He has championed multi-million-dollar businesses and is proficient in unlocking company value by successfully executing growth strategies, institutionalizing controls, and enhancing productivity.

Welcoming Anil as the Director General, Suresh Pattathil, President, OPPI said, "I welcome Anil on board and am confident that with his breadth of experience, we will be able to lead OPPI to achieve its objective of bringing innovative drugs and new therapies for unmet medical needs and drive key advocacy efforts on IP, Innovation, Quality and other areas."

Speaking on his appointment, Anil Matai said, "I am delighted to be a part of the OPPI family during a pivotal moment for healthcare in our nation. I am happy to say that OPPI's focus on the importance of innovation, digitization and quality to drive impact in healthcare, aligns with the Government's vision for India@100. OPPI will continue to drive policy and advocacy discussions with the Government and endeavour to work together with various stakeholders on industry-related issues, to implement sustainable and patient centric solutions."